Methotrexate showed no clear difference in serious adverse events (SAEs) assessed by number of events compared with placebo (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether combinations of antipsychotic drugs changes adverse events: Serious event or requiring discontinuation compared with single antipsychotic drugs (very low certainty).
Regular salmeterol showed no clear difference in asthma‐related non‐fatal serious adverse events ‐ children compared with regular salbutamol (low certainty).
Regular salmeterol showed no clear difference in asthma‐related non‐fatal serious adverse events ‐ children compared with placebo (moderate certainty).
It is very uncertain whether band ligation changes serious adverse events Idiopathic thrombocytopaenic purpura compared with sham or no intervention (very low certainty).
It is very uncertain whether IV ferric carboxymaltose changes serious adverse events ‐ mild to moderate disease (16 weeks) compared with oral iron sulphate (very low certainty).
It is very uncertain whether IV iron isomaltoside changes serious adverse events ‐ remission or mild disease (8 weeks) compared with oral iron sulphate (very low certainty).
It is very uncertain whether IV iron sucrose changes serious adverse events ‐ mild to moderate disease (20 weeks) compared with oral iron sulphate (very low certainty).
It is very uncertain whether IV ferric carboxymaltose changes serious adverse events ‐ mild to moderate disease (12 weeks) compared with IV iron sucrose (very low certainty).
Lower BP target showed no clear difference in total serious adverse events№ of participants: 18165(6 RCTs) compared with standard BP target (moderate certainty).
Sunitinib probably leads to higher serious adverse events (Grade 3 or 4)assessed as: CTCAE v3.0 compared with interferon‐α (IFN‐α) (targeted agent versus classic immunotherapy) (moderate certainty).
It is very uncertain whether the intervention changes serious Adverse Events (Participants with one or more event) (very low certainty).
TDC showed no clear difference in secondary outcome:total serious adverse events at the end of compared with medical therapy (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether oral iron sulphate changes serious adverse events ‐ active or inactive disease (14 days) compared with oral iron hydroxide polymaltose complex (very low certainty).
It is very uncertain whether the intervention changes participants with non‐serious adverse events: up to 3 months' (very low certainty).
Percutaneous techniques showed no clear difference in direct postoperative serious, life‐threatening adverse events compared with surgical techniques (low certainty).